Study of HCD122 in Adults With Non-Hodgkin's or Hodgkin's Lymphoma Who Have Progressed After at Least Two Prior Therapies
A Phase IA/II, Multi-center, Open-label Study of HCD122 Administered Intravenously Once Weekly for Four Weeks in Adult Patients With Advanced Non-Hodgkin's or Hodgkin's Lymphoma Who Have Progressed After at Least Two Prior Therapies (CHIR-12.12-LYM-01)
Sponsor: Novartis Pharmaceuticals
Listed as NCT00670592, this PHASE1/PHASE2 trial focuses on Hodgkin's Lymphoma and Non-Hodgkin's Lymphoma and remains completed. Sponsored by Novartis Pharmaceuticals, it has been updated 9 times since 2008, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Change History
9 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE1/PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Apr 2022 — Jul 2024 [monthly]
Completed PHASE1_PHASE2
-
Jan 2021 — Apr 2022 [monthly]
Completed PHASE1_PHASE2
▶ Show 4 earlier versions
-
Sep 2020 — Jan 2021 [monthly]
Completed PHASE1_PHASE2
-
Jun 2018 — Sep 2020 [monthly]
Completed PHASE1_PHASE2
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE1_PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE1_PHASE2
First recorded
Mar 2008
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Novartis Pharmaceuticals
- XOMA (US) LLC
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Beech Grove, United States, Berlin, Germany, Bologna, Italy, Boston, United States, Chicago, United States, Cologne, Germany, Créteil, France, Ghent, Belgium, Godinne, Belgium, Hong Kong, Hong Kong and 18 more location s